

Novo Nordisk exits R&D in inflammatory disorders

03 September 2014 | News | By BioSpectrum Bureau

Novo Nordisk exits R&D in inflammatory disorders



On September 2, 2014, Novo Nordisk officially announced its decision to discontinue all its R&D activities within inflammatory disorders.

The company said that it will increase its focus and efforts more within diabetes prevention and treatment, obesity and diabetes complications.